“…This finding generated considerable excitement when subsequently verified in large numbers of studies and in many independent laboratories (Kolata, 1986;Suzdak et al, 1986b;Lister and Nutt, 1987;Syapin et al, 1987;Hellevuo and Korpi, 1988;Lister and Nutt, 1988;Ticku and Kulkarni, 1988;Dar, 1992Dar, , 1995, but see (Hellevuo and Korpi, 1988) Given the surprising effectiveness of Ro15-4513 (and the complete ineffectiveness of the close structural analog flumazenil) in reversing pharmacologically relevant EtOH effects, it may not be surprising that there were skeptics that argued it must be the weak GABA A R blocking activity (partial inverse agonism) of Ro15-4513 that must be responsible for the alcohol antagonism (Lister and Nutt, 1987;Britton et al, 1988). However, almost all other negative modulators of GABA receptors (a.k.a., inverse agonists) do not act as alcohol antagonists (for recent review see (Wallner et al, 2006a)). Two exceptions of inverse agonists that do show alcohol antagonist actions are the Ro15-4513 structural analogs, RY080 and RY024, that also have been reported to show behavioral alcohol antagonism (McKay et al, 2004;Cook et al, 2005); these compounds also bind with high affinity to the [ 3 H] Ro15-4513/alcohol site on α4β3δ receptors .…”